Literature DB >> 16531849

The futility of the clinical pulmonary infection score in trauma patients.

Martin A Croce1, Joseph M Swanson, Louis J Magnotti, Jeffrey A Claridge, Jordan A Weinberg, G Christopher Wood, Bradley A Boucher, Timothy C Fabian.   

Abstract

INTRODUCTION: The Clinical Pulmonary Infection Score (CPIS) has received much attention recently. Advocates have touted its use for the diagnosis and duration of therapy in patients with ventilator-associated pneumonia (VAP). However, little has been written about its utility in trauma patients. The clinical, physiologic, and radiologic components of the CPIS may be difficult to differentiate from the systemic effects of injury. Quantitative cultures of the lower airway have been shown to be efficacious in differentiating VAP from the systemic inflammatory response syndrome (SIRS). In this study, we evaluated the potential use of CPIS as the sole means for diagnosis of VAP in critically injured patients.
METHODS: Patients were identified from the VAP database maintained in our Level I trauma center. Only those who had CPIS calculated at the time of bronchoscopy with BAL were included. VAP required >or=10 colonies/mL on quantitative BAL for diagnosis. Antibiotic therapy was based on quantitative BAL results. Patients with <10 colonies/mL were diagnosed with SIRS. Sensitivity and specificity of a CPIS>6 for VAP diagnosis (confirmed by BAL) were calculated.
RESULTS: In all, 158 patients underwent 285 BALs. The overall incidence for VAP was 42%. Patients with episodes of VAP and SIRS were well matched for age, Injury Severity Score, APACHE II score, and Glasgow Coma Scale score. The average CPIS was 6.8 in patients with SIRS and 6.9 for those with VAP. Using a CPIS>6 as the threshold for VAP only yielded a sensitivity of 61% and a specificity of 43%.
CONCLUSIONS: CPIS cannot differentiate VAP from SIRS in critically injured patients. Using CPIS to initiate antibiotic therapy in trauma patients could be harmful. Whether CPIS is useful to determine duration of antibiotic therapy is unknown.

Entities:  

Mesh:

Year:  2006        PMID: 16531849     DOI: 10.1097/01.ta.0000204033.78125.1b

Source DB:  PubMed          Journal:  J Trauma        ISSN: 0022-5282


  22 in total

1.  Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as a diagnostic marker of ventilator-associated pneumonia.

Authors:  Steven J Palazzo; Terri A Simpson; Jillian M Simmons; Lynn M Schnapp
Journal:  Respir Care       Date:  2012-12       Impact factor: 2.258

2.  A pilot study of the noninvasive assessment of the lung microbiota as a potential tool for the early diagnosis of ventilator-associated pneumonia.

Authors:  Addison K May; Jacob S Brady; Joann Romano-Keeler; Wonder P Drake; Patrick R Norris; Judith M Jenkins; Richard J Isaacs; Erik M Boczko
Journal:  Chest       Date:  2015-06       Impact factor: 9.410

3.  Identifying missed opportunities to curtail antimicrobial therapy for presumed ventilator-associated pneumonia using the clinical pulmonary infection score.

Authors:  Sean K Gorman; Lynne-Michelle M Stewart; Richard S Slavik; Jane de Lemos; Dean Chittock; Vinay K Dhingra; Juan J Ronco; Harjinder Parwana
Journal:  Can J Hosp Pharm       Date:  2009-05

Review 4.  Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Authors:  Brad Spellberg; George Talbot
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

5.  Microbiogical data, but not procalcitonin improve the accuracy of the clinical pulmonary infection score.

Authors:  Boris Jung; Nathalie Embriaco; François Roux; Jean-Marie Forel; Didier Demory; Jérôme Allardet-Servent; Samir Jaber; Bernard La Scola; Laurent Papazian
Journal:  Intensive Care Med       Date:  2010-03-09       Impact factor: 17.440

6.  Recent advances in defining and benchmarking complications after esophagectomy.

Authors:  Lucas Goense; Jelle P Ruurda; Richard van Hillergersberg
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

Review 7.  Biomarkers for ventilator-associated pneumonia: review of the literature.

Authors:  Steven J Palazzo; Terri Simpson; Lynn Schnapp
Journal:  Heart Lung       Date:  2011-03-21       Impact factor: 2.210

8.  A trial of discontinuation of empiric vancomycin therapy in patients with suspected methicillin-resistant Staphylococcus aureus health care-associated pneumonia.

Authors:  John M Boyce; Olivia-Fabiola Pop; Odaliz Abreu-Lanfranco; Whitney Y Hung; Ann Fisher; Afshin Karjoo; Benjamin Thompson; Zenon Protopapas
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

9.  Bilateral versus unilateral bronchoalveolar lavage for the diagnosis of ventilator-associated pneumonia.

Authors:  Mark A Jonker; Tina M Sauerhammer; Lee D Faucher; Michael J Schurr; Kenneth A Kudsk
Journal:  Surg Infect (Larchmt)       Date:  2012-12-16       Impact factor: 2.150

10.  No Decrease in Early Ventilator-Associated Pneumonia After Early Use of Chlorhexidine.

Authors:  Terrence Wong; Adam B Schlichting; Andrew J Stoltze; Brian M Fuller; Amanda Peacock; Kari K Harland; Azeemuddin Ahmed; Nicholas Mohr
Journal:  Am J Crit Care       Date:  2016-03       Impact factor: 2.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.